RET and medullary thyroid gland carcinoma: Many studies have focused on MTC treatment, such as, proto-oncogene tyrosine-protein kinase receptor Ret (RET) inhibitors, Ras-like protein 1 (RAS) inhibitors, immunotherapy, and peptide receptor radionuclides.